ReviewToward a Personalized Medicine Approach to the Management of Inflammatory Bowel DiseaseMosli, Mahmoud H MBBS1, 2, 3; Sandborn, William J MD2, 4; Kim, Richard B MD5; Khanna, Reena MD1, 2; Al-Judaibi, Bandar MBBS1, 6; Feagan, Brian G MD1, 2 Author Information 1 Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada 2 Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada 3 Department of Medicine, Division of Gastroenterology, King Abdulaziz University, Jeddah, Saudi Arabia 4 Division of Gastroenterology, University of California San Diego, La Jolla, California, USA 5 Department of Medicine, Division of Clinical Pharmacology, Western University, London, Ontario, Canada 6 Department of Medicine, Division of Gastroenterology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia Correspondence: Brian G. Feagan, Robarts Clinical Trials, Robarts Research Institute, 100 Perth Drive, PO Box 5015, London, Ontario, Canada N6A 5K8. E-mail: [email protected] Received 9 January 2014; accepted 30 March 2014 published online 20 May 2014 American Journal of Gastroenterology: July 2014 - Volume 109 - Issue 7 - p 994-1004 doi: 10.1038/ajg.2014.110 Buy Metrics Abstract The medical management of inflammatory bowel disease (IBD) is evolving toward a personalized medicine-based model. Modern therapeutic algorithms that feature use of tumor necrosis factor (TNF) antagonists in combination with immunosuppressive are highly effective when initiated in high-risk patients early in the course of disease. Defined targets that guide intensification of therapy are critical interventions. In this model, therapy is optimized through appropriate pretreatment testing, therapeutic drug monitoring, and patient-based monitoring strategies. This review discusses the current application of personalized medicine to the management of IBD. © The American College of Gastroenterology 2014. All Rights Reserved.